Dainippon Sumitomo diabetes re-jig sees pipeline casualties
This article was originally published in Scrip
Executive Summary
The latest update of Dainippon Sumitomo Pharma's (DSP) pipeline reveals two early-stage losses from its development portfolio for diabetes, where the Japanese firm already has several other products on the market or moving through clinical trials.